Literature DB >> 24308220

Effects of lipoprotein lipase and peroxisome proliferator-activated receptor-gamma gene variants on metabolic syndrome traits.

Tamara Bozina1, Iveta Simić, Jasna Lovrić, Ivan Pećin, Bojan Jelaković, Jadranka Sertić, Zeljko Reiner.   

Abstract

Peroxisome proliferator activated receptor-gamma (PPARG) and lipoprotein lipase (LPL) play important role in lipid homeostasis, insulin resistance and adipogenesis, and their gene variability could be considered as predictive genetic markers for metabolic syndrome (MetSy). The aim of the study was to estimate possible associations of PPARG (Pro12Ala) and LPL PvuII (+/-) polymorphisms with MetSy and its traits. Study included 527 subjects. According to the modified National Cholesterol Education Program Adult Treatment Panel III definitions, subjects were classified into the metabolic syndrome group and control group. Genotyping was performed using polymerase chain reaction-restriction fragment length polymorphism methods. In the total sample, LPL variants were associated with waist circumference (chi2 = 7.263, d.f = 2, p = 0.026) and with BMI (chi2 = 6.549, d.f = 2, p = 0.038), where PvuII (+/+) genotype carriers had the highest risk for increased waist circumference (specific PvuII (+/+) vs. others analysis chi2 = 7.033, p = 0.008) and increased BMI (specific PvuII( +/+) vs. others analysis chi2 = 5.154, p = 0.023). LPL gene variants were also associated with HDL-C levels (chi2 = 6.901, d.f = 2, p = 0.032), where PvuII (-/-) genotype carriers had higher HDL-C values in comparison to others (specific Pvu (+/+) vs. others analysis chi2 = 6.504, p = 0.011). Furthermore, PvuII (-) allele carriers had significantly lower glucose (allele based analysis Add Value = -0.0878, chi2 = 5.878, d.f. = 1, p = 0.015). Significant interaction was detected between PPARG and LPL that affected HDL-C levels in male population (chi2 = 11.790, d.f = 1, p = 0.0006) in the manner that Ala/PvuII(+) contributed to the lowest HDL-C values (Specific Ala/ Pvu(+) vs. others analysis was chi2 = 11.750, p = 0.0006). According to obtained results LPL and PPARG gene variants could be susceptibility factors of obesity and lipid status, contributing to development of MetSy, particularly in males. Because of antiatherogenic function of HDL-C, the identification of genetic variants associated with HDL-C can provide useful information related to genotype-phenotype relationships. Since the interplay between PPARG and LPL gene and gender seems to be significant it could point to the personalized behavioural recommendations for prevention of metabolic and cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24308220

Source DB:  PubMed          Journal:  Coll Antropol        ISSN: 0350-6134


  4 in total

1.  Effect of valsartan on ACAT-1 and PPAR-γ expression in intima with carotid artery endothelial balloon injury in rabbit.

Authors:  Tao Ma; Zhi-Qiang Ma; Xiao-Hui Du; Qiu-Shi Yu; Rong Wang; Li Liu
Journal:  Int J Clin Exp Med       Date:  2015-04-15

2.  ASSOCIATION OF THE HUMAN PPARγ2 PRO12ALA POLYMORPHISM WITH OBESITY IN A POPULATION FROM TURKEY.

Authors:  M A Sözen; M U Özcan; M Çıldır; I H Doğru; A G Aygök; K Ü Balkan
Journal:  Acta Endocrinol (Buchar)       Date:  2018 Oct-Dec       Impact factor: 0.877

3.  Effects of a liquid high-fat meal on postprandial lipid metabolism in type 2 diabetic patients with abdominal obesity.

Authors:  Feng Wang; Huixia Lu; Fukang Liu; Huizhen Cai; Zhixiu Song; Fei Guo; Yulan Xie; Guofang Shu; Guiju Sun
Journal:  Nutr Metab (Lond)       Date:  2017-08-14       Impact factor: 4.169

4.  Pro12Ala Polymorphism on the PPARγ2 Gene and Weight Loss After Aerobic Training: A Randomized Controlled Trial.

Authors:  Glêbia Alexa Cardoso; Darlene Camati Persuhn; Mateus Duarte Ribeiro; Bruno Rafael Virgínio de Sousa; Klécia de Farias Sena; Antônio Eduardo Monteiro de Almeida; João Modesto-Filho; Raquel Suelen Brito da Silva; Alexandre Sérgio Silva
Journal:  Front Physiol       Date:  2020-05-08       Impact factor: 4.566

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.